Label Image (Lbl530021638)
Not available.*
Losartan Potassium
Product Images NDC 53002-1638
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-1638). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Label Image (Lbl530021643)
Lbl530022624
Chemical Structure (Spl Image1 Structure1)
Figure 1 (Spl Image2 Figure1)
The text mentions the names of two medications, Atenolol and Losartan Potassium, and a statistical result indicating a 13% reduction in adjusted risk for a primary endpoint based on a study. The study was conducted for a period of 66 months with measurements taken at various points along the way.*
Figure 2 (Spl Image3 Figure2)
This document appears to be a comparison between two medications, Atenolol and Losartan Potassium. The adjusted risk reduction for Losartan Potassium is listed as 25% with a p-value of 0.001. The text also lists the percentage of patients with fatal/non-fatal stroke at various study months.*
Figure 3 (Spl Image4 Figure3)
The text describes a table (Figure 3) that shows the primary endpoint events within demographic subgroups for a study that compared the effectiveness of Losartan Potassium and Atenolol in preventing stroke. The subgroups include age, gender, race, ISH, diabetes, and history of CVD. The table presents the number of events and rates for each subgroup, as well as hazard ratios with their corresponding 95% confidence intervals. The text also indicates that the symbols in the table are proportional to sample size and provides a note about the adjustment for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 (Spl Image5 Figure4)
This is a graph that shows the percentage of patients with an event over the course of 48 months while taking either Losartan Potassium or a placebo. The Risk Reduction is 16.1% with a p-value of 0.022.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
